175 related articles for article (PubMed ID: 32929682)
1. The Diagnostic Value of Cadherin 17 and CDX2 Expression as Immunohistochemical Markers in Colorectal Adenocarcinoma.
Abouelkhair MB; Mabrouk SH; Zaki SSA; Nada OH; Hakim SA
J Gastrointest Cancer; 2021 Sep; 52(3):960-969. PubMed ID: 32929682
[TBL] [Abstract][Full Text] [Related]
2. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
3. LI-cadherin and CDX2: Useful Markers in Metastatic Gastrointestinal Adenocarcinoma Cells in Serous Cavity Effusion.
Ma H; Yu J; Tang J
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):e75-e80. PubMed ID: 30095466
[TBL] [Abstract][Full Text] [Related]
4. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
[TBL] [Abstract][Full Text] [Related]
5. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
[TBL] [Abstract][Full Text] [Related]
6. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs.
Barbareschi M; Murer B; Colby TV; Chilosi M; Macri E; Loda M; Doglioni C
Am J Surg Pathol; 2003 Feb; 27(2):141-9. PubMed ID: 12548159
[TBL] [Abstract][Full Text] [Related]
7. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Logani S; Oliva E; Arnell PM; Amin MB; Young RH
Mod Pathol; 2005 Jan; 18(1):19-25. PubMed ID: 15389251
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cadherin-17 expression between primary colorectal adenocarcinomas and their corresponding metastases: the possibility of a diagnostic marker for detecting the primary site of metastatic tumour.
Park JH; Seol JA; Choi HJ; Roh YH; Choi PJ; Lee KE; Roh MS
Histopathology; 2011 Jan; 58(2):315-8. PubMed ID: 21323956
[No Abstract] [Full Text] [Related]
9. CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens.
Tanaka S; Saito K; Ito T; Tajima K; Mogi A; Shitara Y; Sano T; Kuwano H
Oncol Rep; 2007 Jul; 18(1):87-92. PubMed ID: 17549351
[TBL] [Abstract][Full Text] [Related]
10. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20+/7- phenotype.
Tot T
Med Sci Monit; 2004 May; 10(5):BR139-43. PubMed ID: 15114262
[TBL] [Abstract][Full Text] [Related]
11. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach.
Ko S; Chu KM; Luk JM; Wong BW; Yuen ST; Leung SY; Wong J
J Pathol; 2005 Apr; 205(5):615-22. PubMed ID: 15732140
[TBL] [Abstract][Full Text] [Related]
12. Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge.
Roy S; Smith MA; Cieply KM; Acquafondata MB; Parwani AV
Diagn Pathol; 2012 Nov; 7():151. PubMed ID: 23121893
[TBL] [Abstract][Full Text] [Related]
13. Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain.
Strickland-Marmol LB; Khoor A; Livingston SK; Rojiani A
Arch Pathol Lab Med; 2007 Nov; 131(11):1686-90. PubMed ID: 17979487
[TBL] [Abstract][Full Text] [Related]
14. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
Bayrak R; Haltas H; Yenidunya S
Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
[TBL] [Abstract][Full Text] [Related]
15. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
[TBL] [Abstract][Full Text] [Related]
16. TTF-1 and napsin A do not differentiate metastatic lung adenocarcinomas from primary esophageal adenocarcinomas: proposal of a novel staining panel.
Aulakh KS; Chisholm CD; Smith DA; Speights VO
Arch Pathol Lab Med; 2013 Aug; 137(8):1094-8. PubMed ID: 23899066
[TBL] [Abstract][Full Text] [Related]
17. CDX2 as a Predictive Biomarker Involved in Immunotherapy Response Suppresses Metastasis through EMT in Colorectal Cancer.
Wang YS; Kou Y; Zhu RT; Han BW; Li CH; Wang HJ; Wu HB; Xia TM; Che XM
Dis Markers; 2022; 2022():9025668. PubMed ID: 36277982
[TBL] [Abstract][Full Text] [Related]
18. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
Suh N; Yang XJ; Tretiakova MS; Humphrey PA; Wang HL
Mod Pathol; 2005 Sep; 18(9):1217-22. PubMed ID: 15803184
[TBL] [Abstract][Full Text] [Related]
19. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
Landau MS; Kuan SF; Chiosea S; Pai RK
Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
[TBL] [Abstract][Full Text] [Related]
20. Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum.
Groisman GM; Bernheim J; Halpern M; Brazowsky E; Meir A
Arch Pathol Lab Med; 2005 Jul; 129(7):920-3. PubMed ID: 15974817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
